Table 1.

Pharmacokinetic Characteristics of Broad-Spectrum Triazoles, Liposomal Amphotericin B, and Echinocandins [48,49,50,51,52].

	Voriconazole	Isavuconazole	Posaconazole	Liposomal Amphotericin B	Caspofungin	Anidulafungin
Dosage	IV: 6 mg/kg Q12 × 24 h, 4 mg/kg Q12 starting Day 2 PO: 200 mg Q12 h	IV: 200 mg Q8 h × 48 h, 200 mg daily starting Day 3 PO: 200 mg Q8 h for 48 h, 200 mg daily starting Day 3	IV: 300 mg Q12 × 24 h, 300 mg daily starting Day 2 Delayed-release: 300 mg Q12 ×24 h, 300 mg daily starting Day 2 Oral suspension: 200 mg TID	IV: 3 mg/kg/day	70 mg daily on Day 1, 50 mg daily starting Day 2	200 mg daily on Day 1, 100 mg starting Day 2
Formulation	PO, IV	PO, IV	PO, IV	IV	IV	IV
Half-Life (h)	6	110–115	27–35	7–10	9–11	24–26
Bioavailability	Oral, 96%	Oral, 98%	Tablet: 54%Oral suspension: Variable	Oral, 9%	Oral, <5%	Oral, <5%
Linear PK	No	High	IV: NoSuspension/Tablet: High	Yes, doses 1–3 mg/kg; No at higher doses	Yes (Animal Model)	Yes (Animal Model)
Renal Excretion	2%	<1%	<1%	4.5%	41%	<1%
CNS Penetration	High	High (Animal Model)	Low	High (Animal Model)	Low (Animal Model)	Low (Animal Model)
Metabolism	CYP2C19, CYP2C9, CYP3A4	CYP3A4/5	UGT	Unknown	Hydrolysis and N-acetylation	Spontaneous biotransformation into inactive peptide